We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) announced that the FDA has approved its semaglutide once-daily pre-filled pen to improve glycaemic control in type II diabetes patients. The GLP-1 receptor agonist will be marketed by the trade name of Ozempic.
The approval of Ozempic was based on results from the phase III SUSTAIN study. The results showed that people with type II diabetes, who are treated with once-weekly semaglutide experienced statistically significant and sustained blood glucose control compared with Merck’s (MRK - Free Report) Januvia (sitagliptin), Astrazeneca’s (AZN - Free Report) once-weekly Bydureon (exenatide extended-release), Sanofi’s (SNY - Free Report) Lantus (insulin glargine) and placebo. Also, the positive recommendation from an FDA Advisory Committee meeting in October 2017 supported the approval.
Novo Nordisk expects to launch Ozempic in United States in the beginning of 2018. As a part of post-approval requirements, the company will conduct a paediatric trial in patients under 18 years.
Meanwhile, Ozempic is under review by several regulatory agencies including the European Medicines Agency, the Japanese Pharmaceuticals and Medical Devices Agency.
Shares of the company have rallied 41.4% compared with the industry’s gain of 15% on a year-to-date basis.
Additionally, Novo Nordisk is making efforts to develop new treatments for diabetes, which is its core area of expertise. In September 2017, the company received approval for its fast acting insulin aspart, Fiasp. Other than semaglutide, its key pipeline candidate includes nonacog beta pegol. In September 2017, the company received approval for its fast acting insulin aspart, Fiasp.
GLP-1 market, which includes Lilly’s Trulicity and AstraZeneca Plc's once-weekly Bydureon Can give tough competition to Novo Nordisk’s semaglutide.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes
Novo Nordisk (NVO - Free Report) announced that the FDA has approved its semaglutide once-daily pre-filled pen to improve glycaemic control in type II diabetes patients. The GLP-1 receptor agonist will be marketed by the trade name of Ozempic.
The approval of Ozempic was based on results from the phase III SUSTAIN study. The results showed that people with type II diabetes, who are treated with once-weekly semaglutide experienced statistically significant and sustained blood glucose control compared with Merck’s (MRK - Free Report) Januvia (sitagliptin), Astrazeneca’s (AZN - Free Report) once-weekly Bydureon (exenatide extended-release), Sanofi’s (SNY - Free Report) Lantus (insulin glargine) and placebo. Also, the positive recommendation from an FDA Advisory Committee meeting in October 2017 supported the approval.
Novo Nordisk expects to launch Ozempic in United States in the beginning of 2018. As a part of post-approval requirements, the company will conduct a paediatric trial in patients under 18 years.
Meanwhile, Ozempic is under review by several regulatory agencies including the European Medicines Agency, the Japanese Pharmaceuticals and Medical Devices Agency.
Shares of the company have rallied 41.4% compared with the industry’s gain of 15% on a year-to-date basis.
Additionally, Novo Nordisk is making efforts to develop new treatments for diabetes, which is its core area of expertise. In September 2017, the company received approval for its fast acting insulin aspart, Fiasp. Other than semaglutide, its key pipeline candidate includes nonacog beta pegol. In September 2017, the company received approval for its fast acting insulin aspart, Fiasp.
GLP-1 market, which includes Lilly’s Trulicity and AstraZeneca Plc's once-weekly Bydureon Can give tough competition to Novo Nordisk’s semaglutide.
Zacks Rank
Novo Nordisk carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>